Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/glycob/cwu062 http://scihub22266oqcxt.onion/10.1093/glycob/cwu062 C4153759!4153759 !24973253     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24973253 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Glycobiology 2014 ; 24 (10 ): 921-5 Nephropedia Template TP {{tp|p=24973253 |t=2014. Galectin-1 links tumor hypoxia and radiotherapy |pdf=|usr=}}{{24973253 }} gab.com Text Galectin-1 links tumor hypoxia and radiotherapy JO: Glycobiology http://www.kidney.de/pget.php?&tw=1&pmid=24973253 #FOAvip Radiation therapy is a main stay in treating solid tumors and plays a significant role in definitive and adjuvant therapy. Unfortunately, local control remains a challenge, in which the success of radiotherapy is largely dictated by tumor hypoxia, DNA damage repair and the antitumor immune response. Extensive efforts have therefore been devoted to targeting the factors that attenuate tumor radiosensitivity, although with limited success. Mounting evidence suggests that tumor and endothelial cells may utilize galectin-1 (Gal-1) for protection against radiation through several mechanisms. Targeting Gal-1 in combination with radiotherapy provides an exciting approach to address several radiation-prohibitive mechanisms. Twit Text FOAVip Galectin-1 links tumor hypoxia and radiotherapy ????Glycobiology http://www.kidney.de/pget.php?&tw=1&pmid=24973253 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24973253 #FOAvip English Wikipedia <ref>{{Cite pmid|24973253 }}</ref> Galectin-1 links tumor hypoxia and radiotherapy #MMPMID24973253 Kuo P ; Le QT Glycobiology 2014[Oct]; 24 (10 ): 921-5 PMID24973253 show ga Radiation therapy is a main stay in treating solid tumors and plays a significant role in definitive and adjuvant therapy. Unfortunately, local control remains a challenge, in which the success of radiotherapy is largely dictated by tumor hypoxia, DNA damage repair and the antitumor immune response. Extensive efforts have therefore been devoted to targeting the factors that attenuate tumor radiosensitivity, although with limited success. Mounting evidence suggests that tumor and endothelial cells may utilize galectin-1 (Gal-1) for protection against radiation through several mechanisms. Targeting Gal-1 in combination with radiotherapy provides an exciting approach to address several radiation-prohibitive mechanisms. |Carcinogenesis/genetics [MESH] |Endothelial Cells/metabolism/pathology/radiation effects [MESH] |Galectin 1/chemistry/*metabolism [MESH] |Humans [MESH] |Hypoxia/metabolism/pathology [MESH] |Neoplasm Metastasis [MESH] |Neoplasms/genetics/pathology/*radiotherapy [MESH] |Neovascularization, Pathologic/genetics/pathology/*radiotherapy [MESH]Galectin-1 links tumor hypoxia and radiotherapy (epmc).pdf DeepDyve Pubget Overpricing